MOLECULAR INFORMATION
Molecular information
- Type
- Dual GLP-1 / glucagon receptor agonist · weekly subcutaneous · investigational
Mazdutide (IBI362) is a dual GLP-1 / glucagon receptor agonist developed by Innovent under license from Eli Lilly. Authorised in China for obesity (2025). No EMA or FDA filing yet.
Status
- Authorised in China (June 2025) for chronic weight management
- Phase 3 outside China not yet initiated
- Not authorised in EU, UK, US
Why we grade it B
Chinese Phase 3 (GLORY-1) showed −14% weight loss at 48 weeks. Regulatory approval in one major market — but no independent Western replication and no EMA submission. The pharmacology mirrors survodutide, providing mechanistic plausibility.